EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Intra-plaque vascularization assessed in contrast-enhanced ultrasound predicts cardiovascular events in type 2 diabetes with no significant carotid atherosclerotic stenosis: a prospective study with therapeutic implications for SGLT2 inhibitor use

Raffaele Marfella iD, Ludovica Vittoria Marfella, Carlo Fumagalli, Luca Rinaldi, Ferdinando Carlo Sasso, Domenico Cozzolino, Francesco Nappo, Ausilia Sellitto, Ciro Romano, Caterina Carusone, Giuseppe Diodato, Pasquale Russo und 15 weitere

European Heart Journal - Imaging Methods and Practice · 06.10.2025 · 3 (4)

DOI: 10.1093/ehjimp/qyaf129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal - Imaging Methods and Practice, online erschienen am 23.10.2025. Verfasst von Raffaele Marfella und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of University and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients with type 2 diabetes mellitus (T2DM) and no significant carotid stenosis are often considered at moderate cardiovascular risk. However, some may harbour biologically active plaques. Intra-plaque vascularization (IPV), detectable in contrast-enhanced ultrasound (CEUS), reflects plaque vulnerability and may enhance risk stratification. We assessed the prognostic value of CEUS-derived IPV and the effects of SGLT2 inhibitors (SGLT2i) on cardiovascular outcomes and inflammatory markers. Methods and results In this 6-year prospective cohort study, 251 asymptomatic T2DM patients with carotid atherosclerosis <50% stenosis were enrolled. IPV was quantified by CEUS and stratified by tertiles. The primary endpoint was major adverse cardiovascular events (MACE: CV death, non-fatal MI, non-fatal stroke, or heart failure hospitalization). Secondary endpoints included changes in VEGF, IL-6, and TNF-α levels. Patients were also stratified by chronic SGLT2i use. High IPV was associated with greater MACE incidence (32.5%) compared with low IPV (7.4%; HR 3.84, 95% CI 1.89–7.78; P < 0.001). SGLT2i-treated patients showed reduced MACE incidence (12.1% vs. 26.3%, P = 0.004), particularly in the high-IPV subgroup (23.1% vs. 38.9%; HR 0.48, 95% CI 0.25–0.91; P = 0.026). Treatment was also linked to significant VEGF (−52.4 vs. −18.6 pg/mL) and IL-6 (−1.9 vs. −0.6 pg/mL) reductions (P < 0.001 for both).

Conclusion

CEUS-detected IPV predicts cardiovascular events in T2DM patients without significant stenosis. SGLT2i may reduce risk by modulating plaque inflammation and angiogenesis. CEUS combined with biomarker profiling may support personalized prevention strategies in diabetes.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorsVEGFcardiovascular outcomescarotid plaquecontrast-enhanced ultrasoundinflammationintra-plaque vascularizationtype 2 diabetes

Autor:innen und Institutionen

  • Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.
  • Pollution and Cardiovascular Diseases Research Centre, University of Campania 'Luigi Vanvitelli', Naples, Italy.
  • Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
  • Department of Cardiology, AORN Antonio Cardarelli, Naples, Italy.
  • Department of Clinical Research, Nefrocenter Research Network, Via XXV Luglio, 160 Cava de Tirreni, Salerno, Italy.

ORCID-Profile: Raffaele Marfella

Förderung

  • Ministry of University and Research

Zitieren

APA

Marfella, R., Marfella, L. V., Fumagalli, C., Rinaldi, L., Sasso, F. C., Cozzolino, D., Nappo, F., Sellitto, A., Romano, C., Carusone, C., Diodato, G., Russo, P., Marfella, L., Tarantino, N. M., Carpinella, G., Furbatto, F., Gentile, S., Guarino, G., Satta, E., …, & Sardu, C. (2025). Intra-plaque vascularization assessed in contrast-enhanced ultrasound predicts cardiovascular events in type 2 diabetes with no significant carotid atherosclerotic stenosis: a prospective study with therapeutic implications for SGLT2 inhibitor use. European Heart Journal - Imaging Methods and Practice, 3(4). https://doi.org/10.1093/ehjimp/qyaf129

Vancouver

Marfella R, Marfella LV, Fumagalli C, Rinaldi L, Sasso FC, Cozzolino D, et al. Intra-plaque vascularization assessed in contrast-enhanced ultrasound predicts cardiovascular events in type 2 diabetes with no significant carotid atherosclerotic stenosis: a prospective study with therapeutic implications for SGLT2 inhibitor use. European Heart Journal - Imaging Methods and Practice. 2025;3(4). doi:10.1093/ehjimp/qyaf129

BibTeX
@article{Marfella2025,
  author = {Marfella, Raffaele and Marfella, Ludovica Vittoria and Fumagalli, Carlo and Rinaldi, Luca and Sasso, Ferdinando Carlo and Cozzolino, Domenico and Nappo, Francesco and Sellitto, Ausilia and Romano, Ciro and Carusone, Caterina and Diodato, Giuseppe and Russo, Pasquale and Marfella, Lorenza and Tarantino, Nicola Maria and Carpinella, Gerardo and Furbatto, Fulvio and Gentile, Sandro and Guarino, Giuseppina and Satta, Ersilia and Bellis, Alessandro and Marinelli, Luca and Donisi, Isabella and D'Onofrio, Nunzia and Mauro, Ciro and Cappabianca, Salvatore and Balestrieri, Maria Luisa and Sardu, Celestino},
  title = {Intra-plaque vascularization assessed in contrast-enhanced ultrasound predicts cardiovascular events in type 2 diabetes with no significant carotid atherosclerotic stenosis: a prospective study with therapeutic implications for SGLT2 inhibitor use},
  journal = {European Heart Journal - Imaging Methods and Practice},
  year = {2025},
  volume = {3},
  number = {4},
  doi = {10.1093/ehjimp/qyaf129}
}
Kostenlos starten →